Navigation Links
Lexicon Announces Proposed $95 Million Common Stock Offering
Date:3/8/2010

t);s.linkTrackVars='prop5,eVar3,prop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='86832442';s.tl(this,'o','ExternalLink');" target='_blank' href="http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sec.gov&esheet=6002071&lan=en_US&anchor=www.sec.gov&index=1">www.sec.gov.  Alternatively, you may obtain a preliminary prospectus supplement and accompanying prospectus as indicated above.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team.  

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements related to Lexicon's expectations regarding the completion, timing and size of the proposed public offering. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. &#
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Lexicon to Report Fourth Quarter and Year End 2009 Financial Results on February 23, 2010
2. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
3. Lexicon to Host Conference Call and Webcast to Review Top-Line Phase 2 Results From Diabetes Trial
4. Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
5. Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome
6. Lexicon Announces Completion of Public Offering of Common Stock
7. Lexicon Announces Pricing of Common Stock in Public Offering
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
10. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
11. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Deutschland, 31. Juli 2014  invendo medical ... („robotischen") Koloskopie-Systems für den Einmalgebrauch, verkündete heute, ... weltweit anerkannter Manager im Bereich Medizintechnik, als ... stößt. Logo - ... hochangesehener globaler Visionär der Medizintechnikbranche. Er war ...
(Date:7/31/2014)... July 31, 2014 Nutrastar International Inc. (OTCQB: ... supplier of premium branded consumer products, including commercially cultivated ... foods, today announced the signing of its first distributor ... expansion to Hubei Province ... Central China . The contract ...
(Date:7/31/2014)... 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... $70.1 million for the second quarter ended June 30, ... revenue for the same period of 2013. ... Assist Systems were sold globally compared to 523 units ...
Breaking Medicine Technology:invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 2invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 3Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 2Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 3Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 4HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 2HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 3HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 4HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 5HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 6HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 7HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 8HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 9HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 10HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 11HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 12
... Who Take DHA Have Healthier Pregnancies, Fewer Premature Births, ... nutritional,experts from a European Union (EU) committee now recommend ... basis with a large amount,of DHA, an essential omega-3 ... growing array of health benefits, nutritional,supplementation of DHA is ...
... Agent Administered in First-In-Human Study to Cancer Patients, ... Pharmaceuticals, Inc.,today announced that its first-in-humans Phase 1 ... is designed to evaluate the safety,pharmacokinetic and pharmacodynamic ... tumors. Study sites include TGen Clinical Research at,Scottsdale ...
Cached Medicine Technology:European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day 2Prolexys Pharmaceuticals Initiates Phase 1 Study 2
(Date:7/31/2014)... Ottawa, Ontario (PRWEB) July 31, 2014 ... s deliver fitness to your home, which now includes ... certified personal trainers have been delivering fitness to clients ... Ottawa. Fitness on the Go is a Canadian owned ... to helping communities achieve a healthier and fitter lifestyle. ...
(Date:7/31/2014)... July 31, 2014 In a front-page ... pharmaceutical giant, Johnson & Johnson, is withdrawing its laparoscopic ... spread undetected cancer. This important story has also ... Today (7/31), the AP (7/30), the Pittsburgh Business Times ... is used during uterine procedures to, “slice up common ...
(Date:7/31/2014)... ARBORA new bill introduced in Congress with bipartisan support ... University of Michigan research, which could improve the health ... spend on the medicines and tests they need most. ... Diane Black and Earl Blumenauer, grew out of a ... the U-M,s Institute for Healthcare Policy and Innovation. It ...
(Date:7/31/2014)... 2014 Dr. Jeff Drake at Drake ... known chiropractors in the area and he has really made ... He is constantly working with new and return patients to ... Those who are in pain or experience daily suffering should ... those who have never visited Drake Chiropractic, Dr. Drake is ...
(Date:7/31/2014)... Long associated with enabling the proliferation of ... by Heat-Shock Factor 1 (HSF1) can also turn ... support malignant progression and metastasis. , The finding, ... the journal Cell , lends new insights ... diagnosis, prognosis, and management of cancer patients. ...
Breaking Medicine News(10 mins):Health News:Fitness on the Go Grows to Ottawa 2Health News:Have You Had a Hysterectomy or Removal of Uterine Fibroids? Morcellator Device Withdrawn From Market Due To Cancer Risk 2Health News:Have You Had a Hysterectomy or Removal of Uterine Fibroids? Morcellator Device Withdrawn From Market Due To Cancer Risk 3Health News:Drake Chiropractic Offers Special to New Patients in Wichita 2Health News:Master HSF supports reprogramming of normal cells to enable tumor growth and metastasi 2Health News:Master HSF supports reprogramming of normal cells to enable tumor growth and metastasi 3
... suffering encountered by men who underwent surgery for hernia was ... delayed surgeries and felt almost no symptoms, after a period ... were also reported to be the same. Most men who ... either minimally symptomatic or asymptomatic. They usually wait until the ...
... doctors and pharmacists in the U.S. are not aware that ... drugs of the same brand name or a similar sounding ... U.S. Food and Drug Administration (FDA) //said medication name mix-ups ... buying and using the wrong medicine. ...
... 12 babies born in New South Wales are due to ... obstetricians working at the private hospitals. ,About 25% ... drugs to initiate labour. // ,The doctors when asked ... as they want that particular doctor to handle their pregnancy. ...
... upset and has sent a letter to the acting head of ... letter he had asked the FDA to provide a full account ... reveled that the tainted tissues were used for the patients in ... into the matter about the case of the Brooklyn funeral home ...
... incidence of Polio in Bihar state has led to much ... state stands unparalled with respect to the number of polio ... for provision of polio drops to children less than 5 ... recently. ,National Cadet Corps volunteers embarked on ...
... The Royal National Institute of Deaf People with collaboration with ... aims at checking the hearing capacity of 28 million people ... is estimated that more than 4 million people in United ... to be treated which requires early diagnosis. ,The ...
Cached Medicine News:Health News:Drug Name Confusion Makes Imports Dangerous: FDA 2Health News:New trend of birth induction is on the rise 2Health News:Bihar Health Officials Worried As Polio Cases Soar 2
Albumin (BCG). Storage temp: 15 -30 C. Linearity: 0.5 - 6.0 g/dl. Expected values: 3.5 - 5.5 g/dl. Available with calibrator. Performs 500 number of tests....
ASAT (GOT) FS (IFCC mod). For determination of ASAT (GOT) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 268 U/L at 30C. Two vials, dry powder reagents...
... The DRS 2000, a uniquely intelligent system, offers ... space saving, 2-level design. Up to 27 reservoirs ... give you the flexibility to tailor your staining ... Two start stations allow for continuous loading; The ...
Medicine Products: